AI Article Synopsis
- Mantle cell lymphoma (MCL) is a type of non-Hodgkin lymphoma that mostly impacts older individuals, representing 3-10% of NHL cases in western countries.
- The variability in MCL outcomes is influenced by clinical characteristics, genetic factors, and molecular features, including the proliferation index and specific mutations like TP53.
- Recent advancements in treatment, particularly with novel agents like BTK inhibitors, are improving the ability to customize therapies based on individual patient and disease traits, leading to better management strategies.
Article Abstract
Mantle cell lymphoma (MCL) primarily affects older adults, accounting for 3-10% of all non-Hodgkin lymphoma (NHL) in western countries. The disease course of MCL is heterogenous; driven by clinical, cytogenetics, and molecular features that shape differences in outcomes, including proliferation index, MIPI scores, and mutational profile such as TP53 aberration. The advent of novel agents has fundamentally evolved the treatment landscape for MCL with treatment strategies that can now be more effectively tailored based on both patient- and disease-specific factors. In this review, we discuss the major classes of novel agents used for the treatment of MCL, focusing on efficacy and notable toxicities of BTK inhibitors. We further examine effective novel combination regimens and, lastly, discuss future directions for the evolution of targeted approaches for the treatment of MCL.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/10428194.2023.2264430 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!